As all of us navigate further into the New Year, I am overjoyed to recollect how the year 2016 enabled Oviya MedSafe to metamorphose to what we are today with our established credentials in building pharmacovigilance strategies for our clients, in this January 2017 edition of our newsletter!
Until 2015, although Oviya MedSafe handled several projects for fulfilling the drug safety obligations of many multinational pharmaceutical and biotechnology companies (both innovators and generic drug manufacturers/marketers) mandated by the concerned regulatory agencies including the EMA and the FDA, we were either requested by our clients to perform specific tasks in line with their drug safety systems and business needs or asked to provide strategic inputs with deliverables limited only to serve as documentation of our consulting support. However, our new clients in the year 2016 transformed Oviya MedSafe into their Strategic Pharmacovigilance Partner, thanks to our unrelenting compliance with our own philosophy which facilitated our consistent growth from a start-up organization in 2012 to a trustworthy brand name to reckon with in the global pharmacovigilance domain in 2016.
In 2016, Oviya MedSafe had several opportunities to set up and start running pharmacovigilance systems for a variety of clients who signed end-to-end long-term contracts with us. Such clients ranged from absolute beginners in pharmacovigilance to those having some pharmacovigilance structure, albeit inadequate, in place. Oviya MedSafe’s innate ready-to-deploy SOPs with a customized approach for each client, solid regulatory pharmacovigilance intelligence, vibrant team of well-experienced pharmacovigilance professionals, robust quality assurance department, mature project management expertise and on-demand access to a cost-effective 21 CFR Part 11 and E2B compliant global drug safety software database were recognized as boons by these new clients who partnered with Oviya MedSafe, especially those who approached us at the eleventh hour with little time left for us before going live. The fact that our clients find us comfortable partners to work with and rather feel protected by being our clients continues to result in successful referral businesses for Oviya MedSafe, which symbiosis we anticipate to leverage for the benefit of all the concerned parties in 2017 too and beyond.
Moving on to updates about our plan for celebrating Oviya MedSafe’s 5th Anniversary (first announced in our December 2016 newsletter), we have identified 17th & 18th March 2017 as the dates for the pharmacovigilance workshop we will be organizing at Coimbatore, India for students and aspiring professionals. By conducting this 2-day workshop, we intend to enhance the appetite of Medical/Pharmacy/Life Sciences students & young graduates to take up pharmacovigilance as a career and to engage healthcare professionals in a dialogue on how the adoption of pharmacovigilance in their practice could be improved for patient safety. The workshop will have invited talks, lectures, Q & A sessions, panel discussions, hands on exercises and pre-selected free paper/poster award presentations by delegates. Continuing Medical/Pharmacy Education (CME/CPE) credit points, as applicable, will be applied for. The formal brochure of the workshop along with the agenda and the modus operandi & delegate registration fee details will be released within a couple of weeks. For any queries regarding this workshop, please write to firstname.lastname@example.org.
On another note, I am delighted to inform you about the continuation of my relationship with the ‘Pharmacovigilance Day‘ series of events conceptualized by Life Science Academy, a business unit of Italy-based EasyB Srl. I will be the Chair of the UK Pharmacovigilance Day 2017 conference to be held at London, UK on Tuesday 6th June 2017 and the Indian Pharmacovigilance Day 2017 conference to be held at Hyderabad, India on Friday 28th July 2017. In addition, Oviya MedSafe will be a sponsor of the latter event. More details about these conferences will be available on the websites of the respective conferences as the agenda get structured and speakers are finalized. Please do bookmark these dates and kindly ensure your participation to make these events successful.
Before signing off, I wish to share with you my invited article “Pharmacovigilance Programme of India: SWOT Analysis” which has been published in the Drug Information Association‘s (DIA) digital magazine ‘Global Forum‘, in its just-released February 2017 special edition on ‘Product Safety’ that features content created by global leaders in the Drug Safety arena. The article is available on the URL http://www.globalforum-online.org/Feb2017/index.html?page=22 for free reading, irrespective of the reader’s DIA membership status. I welcome your feedback on this article and will look forward to hearing from you. Please do not hesitate to share the link to this article with anybody who may find this subject interesting.
Waiting to re-connect with you through our February 2017 newsletter,
With thanks & regards,
Dr J Vijay Venkatraman
MBBS, F. Diab., MBA, FPIPA (UK)
Managing Director & CEO,
Oviya MedSafe Pvt Ltd,
Oviya MedSafe UK Ltd,
Follow us on: Facebook, Google Plus, LinkedIn & Twitter